tbuckley/cabot-search huggingface dataset:
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Authors: Wenjuan Yu, Ping Li, Lili Zhou, Min Yang, Shiguang Ye, Dan Zhu, Jiaqi Huang, Xin Yao, Yan Zhang, Lanfang Li, Jing Zhao, Kevin Zhu, Jing Li, Chengxiao Zheng, Liping Lan, Hui Wan, Yihong Yao, Huilai Zhang, Daobin Zhou, Jie Jin, Aibin Liang
Journal: Blood (2025)

Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor (CAR) T-cell, targets and eliminates CD19/CD20 positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin Lymphoma (r/r B-NHL). Patients with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose of prizlon-cel. The primary endpoints were dose-limiting toxicity (DLT) and incidence and severity of treatment-emergent adverse events (TEAEs). Secondary endpoints included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of the 48 patients infused prizlon-cel, 44 had large B-cell lymphoma (LBCL). No patient experienced DLT. Cytokine release syndrome occurred in 93.8% of patients, with only one case of grade 3. Immune effector cell-associated neurotoxicity syndrome occurred in 6.3% of patients, with no grade 3 or higher events. The most common grade 3 or higher TEAEs were neutropenia (83.3%) and leukopenia (50%). The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow up of 30.0 months, median DOR, PFS, and OS were all not reached. The Kaplan-Meier estimate of 2-year DOR, PFS and OS rates were 66.0%, 62.6%, and 76.5%, respectively. Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age
Authors: Mark J Bolland, Zaynah Nisa, Anna Mellar, Chiara Gasteiger, Veronica Pinel, Borislav Mihov, Sonja Bastin, Andrew Grey, Ian R Reid, Greg Gamble, Anne Horne
Journal: New England Journal of Medicine (2025)

BackgroundZoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate administration would prevent vertebral fractures in early postmenopausal women is unknown.MethodsWe conducted a 10-year, prospective, double-blind, randomized, placebo-controlled trial involving early postmenopausal women (50 to 60 years of age) with bone mineral density T scores lower than 0 and higher than −2.5 (scores of −1 or higher typically indicate normal bone mineral density) at the lumbar spine, femoral neck, or hip. Participants were randomly assigned to receive an infusion of zoledronate at a dose of 5 mg at baseline and at 5 years (zoledronate–zoledronate group), zoledronate at a dose of 5 mg at baseline and placebo at 5 years (zoledronate–placebo group), or placebo at both baseline and 5 years (placebo–placebo group). Spinal radiographs were obtained at baseline, 5 years, and 10 years. The primary end point was morphometric vertebral fracture, which was assessed semiquantitatively and defined as at least a 20% change in vertebral height from that seen on the baseline radiograph. Secondary end points were fragility fracture, any fracture, and major osteoporotic fracture.Download a PDF of the Plain Language Summary.ResultsOf 1054 women with a mean age of 56.0 years at baseline, 1003 (95.2%) completed 10 years of follow-up. A new morphometric fracture occurred in 22 women (6.3%) in the zoledronate–zoledronate group, in 23 women (6.6%) in the zoledronate–placebo group, and in 39 women (11.1%) in the placebo–placebo group (relative risk, zoledronate–zoledronate vs. placebo–placebo, 0.56 [95% confidence interval {CI}, 0.34 to 0.92; P=0.04]; and zoledronate–placebo vs. placebo–placebo, 0.59 [95% CI, 0.36 to 0.97; P=0.08]). The relative risk of fragility fracture, any fracture, and major osteoporotic fracture was 0.72 (95% CI, 0.55 to 0.93), 0.70 (95% CI, 0.56 to 0.88), and 0.60 (95% CI, 0.42 to 0.86), respectively, when zoledronate–zoledronate was compared with placebo–placebo and 0.79 (95% CI, 0.61 to 1.02), 0.77 (95% CI, 0.62 to 0.97), and 0.71 (95% CI, 0.51 to 0.99), respectively, when zoledronate–placebo was compared with placebo–placebo.ConclusionsTen years after trial initiation, zoledronate administered at baseline and 5 years was effective in preventing morphometric vertebral fracture in early postmenopausal women. (Funded by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12612000270819.) Quick Take Fracture Prevention with Infrequent Zoledronate 2m 12s
Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia
Authors: Julian Ronnacker, Michael Grau, Maximilian Klasmeier, Christian Klesse, Henning Baldauf, Stefan Abert, Andrew F. Berdel, Friederike T. Füsser, Sarah Sandmann, Jorn C Albring, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Lina Kolloch, Philipp Berning, Annika Scheller, Klaus Wethmar, Hartmut Schmidt, Bernhard Schlüter, Wolfgang E. Berdel, Benjamin N. Ostendorf, Sohail F. Tavazoie, Jan-Henrik Mikesch, Georg Lenz, Katharina Fleischhauer, Johannes Schetelig, Matthias Stelljes, Christoph Schliemann
Journal: Blood (2025)
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Authors: Charles E Geyer, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo, Hans H Fischer, Véronique D'Hondt, Alison K Conlin, Valentina Guarneri, Irene L Wapnir, Christian Jackisch, Claudia Arce-Salinas, Peter A Fasching, Michael P DiGiovanna, John P Crown, Pia Wuelfing, Zhimin Shao, Elena Rota Caremoli, Hervé R Bonnefoi, Bryan T Hennessy, Ljiljana Stamatovic, Hugo Castro-Salguero, Adam M Brufsky, Adam Knott, Asna Siddiqui, Chiara Lambertini, Thomas Boulet, Beatrice Nyawira, Eleonora Restuccia, Sibylle Loibl
Journal: New England Journal of Medicine (2025)

BackgroundPatients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with trastuzumab alone.MethodsWe randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive T-DM1 or trastuzumab for 14 cycles. Here, we report the prespecified final analysis of invasive disease–free survival and the second interim analysis of overall survival.Download a PDF of the Plain Language Summary.ResultsWith a median follow-up of 8.4 years, T-DM1 sustained the improvement in invasive disease–free survival over trastuzumab (unstratified hazard ratio for invasive disease or death, 0.54; 95% confidence interval [CI], 0.44 to 0.66). Seven-year invasive disease–free survival was 80.8% with T-DM1 and 67.1% with trastuzumab (difference, 13.7 percentage points). T-DM1 also led to a significantly lower risk of death than trastuzumab (unstratified hazard ratio, 0.66; 95% CI, 0.51 to 0.87; P=0.003). Seven-year overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab (difference, 4.7 percentage points). Adverse events of grade 3 or higher were noted in 26.1% of the patients in the T-DM1 group and 15.7% of those in the trastuzumab group.ConclusionsAs compared with trastuzumab, T-DM1 improved overall survival with sustained improvement in invasive disease–free survival among patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. (Funded by F. Hoffmann–La Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472.) Quick Take Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer 2m 35s
Transient Receptor Potential V Channels Are Essential for Glucose Sensing by Aldolase and AMPK
Authors: Mengqi Li, Chen-Song Zhang, Yue Zong, Jin-Wei Feng, Teng Ma, Meiqin Hu, Zhizhong Lin, Xiaotong Li, Changchuan Xie, Yaying Wu, Dong Jiang, Ying Li, Cixiong Zhang, Xiao Tian, Wen Wang, Yanyan Yang, Jie Chen, Jiwen Cui, Yu-Qing Wu, Xin Chen, Qing-Feng Liu, Jianfeng Wu, Shu-Yong Lin, Zhiyun Ye, Ying Liu, Hai-Long Piao, Li Yu, Zhuan Zhou, Xiao-Song Xie, D. Grahame Hardie, Sheng-Cai Lin
Journal: Cell Metabolism (2025)
CD4+ T cells re-wire granuloma cellularity and regulatory networks to promote immunomodulation following Mtb reinfection
Authors: Joshua D. Bromley, Sharie Keanne C. Ganchua, Sarah K. Nyquist, Pauline Maiello, Michael Chao, H. Jacob Borish, Mark Rodgers, Jaime Tomko, Kara Kracinovsky, Douaa Mugahid, Son Nguyen, Qianchang Dennis Wang, Jacob M. Rosenberg, Edwin C. Klein, Hannah P. Gideon, Roisin Floyd-O’Sullivan, Bonnie Berger, Charles A. Scanga, Philana Ling Lin, Sarah M. Fortune, Alex K. Shalek, JoAnne L. Flynn
Journal: Immunity (2025)
Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy
Authors: Fangchen Gong, Xiangtao Zheng, Shanzhi Zhao, Huan Liu, Erzhen Chen, Rongli Xie, Ranran Li, Ying Chen
Journal: MedComm (2025)

Abstract Disseminated intravascular coagulation (DIC) is a complex and serious condition characterized by widespread activation of the coagulation cascade, resulting in both thrombosis and bleeding. This review aims to provide a comprehensive overview of DIC, emphasizing its clinical significance and the need for improved management strategies. We explore the primary causes of DIC, including sepsis, trauma, malignancies, and obstetric complications, which trigger an overactive coagulation response. At the molecular level, DIC is marked by excessive thrombin generation, leading to platelet and fibrinogen activation while simultaneously depleting clotting factors, creating a paradoxical bleeding tendency. Diagnosing DIC is challenging and relies on a combination of existing diagnostic criteria and laboratory tests. Treatment strategies focus on addressing the underlying causes and may involve supportive care, anticoagulation therapy, and other supportive measures. Recent advances in understanding the pathophysiology of DIC are paving the way for more targeted therapeutic approaches. This review highlights the critical need for ongoing research to enhance diagnostic accuracy and treatment efficacy, ultimately improving patient outcomes in those affected by DIC.
Winter viruses: we can do more to prevent a surge in cases
Authors: Lindsay Broadbent
Journal: BMJ (2025)

Winter viruses: we can do more to prevent a surge in cases An extended flu vaccine rollout would benefit public health and the economy, writes Lindsay Broadbent Lindsay Broadbent assistant professor in virology Every year, as the weather turns colder, we can't go far without hearing someone cough or sniffle.The "cold and flu" season is nothing new, but we need to do more to tackle winter illness.
Sleep alterations in major depressive disorder and insomnia disorder: a network meta-analysis of polysomnographic studies
Authors: Caterina Leitner, Francesca Dalle Piagge, Tijana Tomic, Federica Nozza, Elisabetta Fasiello, Vincenza Castronovo, Luigi De Gennaro, Chiara Baglioni, Luigi Ferini-Strambi, Andrea Galbiati
Journal: Sleep Medicine Reviews (2025)
Promoting healthy digital device usage: recommendations for youth and parents
Authors: Joseph Firth, Marco Solmi, Johanna Löchner, Samuele Cortese, José Francisco López‐Gil, Katarzyna Machaczek, Jeffrey Lambert, Hannah Fabian, Nicholas Fabiano, John Torous
Journal: World Psychiatry (2025)

Young people's usage of digital devices is currently a central topic of interest for researchers, clinicians and the general public, particularly with regards to the impact of social media on adolescents' mental health. Notably, the duration of screen time is not the primary determinant of mental health outcomes1, 2. Rather, the "quality" of an individual's device usage patterns, experiences and interactions online, and how they correlate with other lifestyle variables (e.g., sedentary time and sleep) appear to matter most1, 3, 4. Other than avoiding the more clear-cut "online harms" (e.g., addictive behaviors, cyberbullying, and online blackmail or exploitation), there is a lack of consensus on how youth can improve the "quality" of their online time. This is in part because the details of what constitutes "healthy" device usage are unclear, and likely differ with regards to sociodemographic factors1. Here we sought to produce a simplified set of recommended actions to promote adolescents' healthy digital device usage. We assembled a multidisciplinary team of individuals with expertise across child and adolescent mental health, social media research, behavior change interventions, and public health. We then identified and reviewed recently published guideline/recommendation articles, online resources and reports from independent think tanks – particularly those that included feedback from young people themselves. We checked these resources for directly actionable advice, rather than general principles on healthy usage patterns. We then considered the recommended actions from such documents alongside the underlying scientific evidence and the team's experience, in order to put forward the top three tips for healthy device usage in adolescents. We also produced a further set of recommendations for parents who wish to implement such changes in their family units. As digital device usage has been increasing worldwide, the impact on youth mental health has emerged as a central concern. We sought to produce a set of best-practice approaches, on the basis of available evidence and guidelines, for adolescents and their parents looking to improve their device usage patterns. Ultimately, however, managing this issue at a societal level will require a whole system approach, involving partnerships between governments, social media companies, and health care organizations. To propel this, more high-quality research is urgently needed to determine what actions policy makers, clinicians and the public can take, including the perspectives of young people themselves.
Antibody functionalized curcuma-derived extracellular vesicles loaded with doxorubicin overcome therapy-induced senescence and enhance chemotherapy
Authors: Zhaoming Guo, Yi Zhang, Yuwei Gong, Guqing Li, Jiawei Pan, Danni Dou, Kun Ma, Changhao Cui, Yubo Liu, Xudong Zhu
Journal: Journal of Controlled Release (2025)
Zidebactam restores cefiderocol sensitivity in resistant bacteria
Authors: Chen Xu, Xiaofan Li, Guangfen Zhang, Chunli Li, Jiayi You, Chenjie Zhang, Yuanyuan Li, Yunbing Li, Xiangkun Zeng, Lili Huang, Mi Zhou, Yi Yang, Jiani Jiang, Ruichao Li, Shigui Yang, Ning Dong
Journal: Journal of Infection (2025)
TGR5 attenuates DOCA-salt hypertension through regulating histone H3K4 methylation of ENaC in the kidney
Authors: Long Xu, Xinyan Wu, Luosha Long, Suchun Li, Meiying Huang, Meng Li, Pinning Feng, Moshe Levi, Wei Chen, Lei Wang, Chunling Li, Weidong Wang
Journal: Metabolism (2025)
Examining the under-representation of black researchers in sports science and sports medicine publications: ‘You Can’t be what You Can’t See’
Authors: João Victor Rosa de Freitas, Naiane Silva Morais, Jéssika Teodoro Santos, Rízia Rocha-Silva, Tatiana Silva da Conceição, Rafaela Gomes dos Santos, Braulio Evangelista de Lima, Rodrigo Luiz Vancini, Marilia Santos Andrade, Ricardo Borges Viana, Claudio Andre Barbosa de Lira
Journal: British Journal of Sports Medicine (2025)

Objectives This study evaluated the representation of black researchers as authors of articles published in four peer-reviewed journals with the highest impact factors (IFs) in the field of sports science and sports medicine. Methods An analysis was conducted on articles published between 2018 and 2022 in four leading sports science journals with high IFs (2022): The British Journal of Sports Medicine, Journal of Sport and Health Science, Sports Medicine and Exercise Immunology Review. Data extraction from the articles included the researcher’s names, sex/gender, total number of authors, number of black authors, their position in the author list, publication year, article title and type and digital object identifier. Sex/gender and race/skin colour were identified using publicly available photographs and methodologies aligned with previous studies and Brazilian racial heteroidentification practices. Results The analysis included 1737 articles and 11 158 authors. Only 144 (1.30%) authors were identified as black, of which only 38 were women, corresponding to 0.34% and 26.4% of total authors and total black authors, respectively. When considering authorship positions, only 16 (0.92%) were the first author and 19 (1.09%) were the last (senior) author. Merely 13 (0.75%) articles had two or more black authors. Conclusion Our findings reveal a significant under-representation of black authors in sports science and sports medicine publications from high-impact journals, particularly in prominent authorship positions. Active initiatives and policies are urgently required to address and mitigate this inequity.
Short term complications of conisation and long term effects on fertility related outcomes in Denmark: register based nationwide cohort study
Authors: Mathias Aagaard, Jessica á Rogvi, Frederikke Modin, Dagny Nicolaisdóttir, Volkert Siersma, John Brandt Brodersen
Journal: BMJ (2025)

Abstract Objective To report on complications of conisation and its effects on fertility and stenosis. Design Register based nationwide cohort study on routinely collected data using several linked databases. Setting Primary and secondary care in Denmark, 2006-18. Population The conisation cohort comprised 48 048 conisations on women aged 23-65 who had undergone conisation within 120 days of a cervical biopsy. The biopsy cohort comprised 48 048 biopsies on women who had undergone a cervical biopsy but not conisation who were matched by age and time of procedure. Women were excluded from the conisation cohort before long term outcome analyses if they had undergone hysterectomy, resection of the uterus, or had cervical cancer or any long term outcomes within the 10 years before their conisation. Main outcome measures Bleeding, infection, and gynaecological operations within 30 days of conisation (stratified by age, year of conisation, and number of previous conisations) and long term risk of fertility treatment, fertility consultation, stenosis, cervical dilatation, infertility diagnoses, and death at any point after conisation. Long term outcomes were followed up until death, emigration, diagnosis of cervical cancer, hysterectomy or resection of uterus, or the end of 2018. Long term outcomes were analysed with incidence rate ratios from Cox regression models. Results Bleeding, infection, and gynaecological operations were registered for 2.81% (n=1351), 0.48% (n=231), and 3.95% (n=1897) of all conisations within 30 days of the procedure, respectively. Women in the conisation cohort had increased risk of stenosis (incidence rate ratio 14.81, 95% confidence interval 7.55 to 29.05, 0.41% v 0.03% (n=176 v 12)) and cervical dilatation (2.68, 2.41 to 2.97, 4.01% v 1.58% (n=1735 v 668)) compared with women in the biopsy cohort. No significant differences were observed for the other outcomes when adjusting for baseline covariates (such as age and region of residence). Cervical suturing after bleeding was associated with a substantial increase in the risk of stenosis and cervical dilatation. Conclusion This study found higher rates of complications within 30 days of conisation than previous studies with comparable outcome definitions, and a substantially increased risk of stenosis and cervical dilatation for women who had cervical suturing to treat bleeding after conisation. However, these results were based on few events in a small subgroup, and are therefore associated with major uncertainty. This study supports previous findings that conisation does not generally increase rates of infertility treatment or infertility diagnoses.
Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells
Authors: Youkun Bi, Xinlong Qiao, Zhaokui Cai, Hailian Zhao, Rong Ye, Qun Liu, Lin Gao, Yingqi Liu, Bo Liang, Yixuan Liu, Yaning Zhang, Zhiguang Yang, Yanyun Wu, Huiwen Wang, Wei Jia, Changqing Zeng, Ce Jia, Hongjin Wu, Yuanchao Xue, Guangju Ji
Journal: Cell Metabolism (2025)
Bicalutamide does not raise transaminases clinically significantly compared to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Authors: Katie Burgener, Brian DeBosch, Jinli Wang, Christopher Lewis, Cynthia Herrick
Journal: International Journal of Transgender Health (2025)

Background Bicalutamide is a potential anti-androgen for transgender individuals with feminizing embodiment goals, but use is limited because of hepatotoxicity in cisgender men with prostate cancer. This study compared transaminase changes in transfeminine adolescents and young adults (AYA) using low dose bicalutamide with individuals using another androgen blockade.
Parental stress and mental health among transgender parents
Authors: Haibing Yang, Xiaona Na, Yuefeng Tan, Yulin Zhang, Xiaojin Shi, Ai Zhao
Journal: International Journal of Transgender Health (2025)

Background Parental stress impacts individual health and the development of the next generation, but there is a lack of comprehensive research on parental stress among transgender parents in China. This study is the first to investigate parental stress and mental health among transgender parents and identify potential influencing factors.